Cargando…
Use of rituximab in idiopathic retroperitoneal fibrosis
BACKGROUND: Retroperitoneal fibrosis (RPF) is characterized by the proliferation of fibrous tissue in the retroperitoneum. The majority of RPF cases are due to idiopathic or IgG4-related disease. Recent studies on IgG4-related disease have shown rituximab to be an effective treatment. The current fi...
Autores principales: | Boyeva, Veronika, Alabsi, Hatim, Seidman, Michael A., Paterson, Ryan, Kur, Jason, Chen, Luke Y. C., Chang, Silvia D., Carruthers, Mollie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409628/ https://www.ncbi.nlm.nih.gov/pubmed/32775962 http://dx.doi.org/10.1186/s41927-020-00140-9 |
Ejemplares similares
-
Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis
por: Wallwork, Rachel, et al.
Publicado: (2018) -
Rethinking Ormond’s Disease: “Idiopathic” Retroperitoneal Fibrosis in the Era of IgG4-Related Disease
por: Khosroshahi, Arezou, et al.
Publicado: (2013) -
Pediatric idiopathic retroperitoneal fibrosis
por: Subramani, Ashwin V., et al.
Publicado: (2019) -
Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis
por: Wang, Kunkun, et al.
Publicado: (2021) -
An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab
por: Hamdan, Ahmad, et al.
Publicado: (2021)